4d Molecular Therapeutics, Inc. (FDMT) Stock Price & Analysis
4d Molecular Therapeutics, Inc. (FDMT) fell 2.99% to USD 10.07 as of July 25, 2026 at 03:04 UTC, according to Nexqual real-time market data.
FDMT last closed at USD 10.38; the session ranged USD 9.91–10.46 on volume of 678,769 shares. Market capitalization is $526.42M, with a 52-week range of USD 4.27–14 (NMS). Source: Nexqual, July 25, 2026 at 03:04 UTC.
Key Statistics (as of July 25, 2026 at 03:04 UTC)
| Price | USD 10.07 |
|---|---|
| Change | ▼ 2.99% (down) |
| Previous Close | USD 10.38 |
| Open | USD 10.38 |
| Day Range | USD 9.91 – 10.46 |
| 52-Week Range | USD 4.27 – 14 |
| Volume | 678,769 shares |
| Market Cap | $526.42M |
| Exchange | NMS |
Technical Analysis (FDMT)
Nexqual's technical model rates FDMT "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:04 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.13 (neutral) |
| vs SMA50 | Below (USD 10.39) |
| MACD | -0.03 (negative) |
Analyst Ratings (FDMT)
Wall Street analysts rate FDMT "Buy" based on 9 analysts, with a mean price target of USD 28.22 (range USD 17–36), per Nexqual as of July 25, 2026 at 03:04 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 28.22 |
| High Target | USD 36 |
| Low Target | USD 17 |
| Buy / Hold / Sell | 9 / 2 / 0 |
Earnings (FDMT)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -1.01 |
| Revenue Estimate | $2.66M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.01 vs est -1 ▼ miss |
| 2025-12-31 | USD 0.43 vs est -0.53 ▲ beat |
| 2025-09-30 | USD -1.01 vs est -0.98 ▼ miss |
| 2025-06-30 | USD -0.98 vs est -0.69 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
Financials & Fundamentals (FDMT)
| Total Revenue | $88.24M |
|---|---|
| Revenue Growth (YoY) | +21664.30% |
| Gross Margin | -145.66% |
| Operating Margin | -2416.15% |
| Profit Margin | -182.34% |
| ROE | -34.92% |
| Debt / Equity | 4.55 |
| Current Ratio | 9.34 |
| Total Cash | $390.89M |
| Total Debt | $20.54M |
| Free Cash Flow | $-69.36M |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
Financial Health Score (FDMT)
Nexqual rates 4d Molecular Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:04 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $391M cash vs $21M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$69M, burning cash |
| Efficiency | Critical — ROE -35%, ROA -21.4% |
Ownership (FDMT)
| Insider Ownership | +3.21% |
|---|---|
| Institutional Ownership | +101.82% |
| Shares Outstanding | 52.28M |
| Float | 39.01M |
| Short % of Float | +29.42% |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
Leadership (FDMT)
4d Molecular Therapeutics, Inc. is led by David H. Kirn (age 63), Co-Founder, President, CEO & Director, per Nexqual as of July 25, 2026 at 03:04 UTC.
| Co-Founder, President, CEO & Director | David H. Kirn (age 63) |
|---|---|
| Executive Chairman | John F. Milligan (age 64) |
| CFO and Principal Financial & Accounting Officer | Kristian Humer (age 49) |
| Chief Scientific Advisor | Noriyuki Kasahara (age 62) |
Major Backers & Investors (FDMT)
Notable institutional backers of 4d Molecular Therapeutics, Inc. include Janus Henderson Group PLC, RA Capital Management, L.P., Goldman Sachs, according to Nexqual as of July 25, 2026 at 03:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Janus Henderson Group PLC | 10.04% |
| RA Capital Management, L.P. | 9.66% |
| Goldman Sachs | 8.04% |
| Novo Holdings A/S | 6.98% |
| BVF Inc. | 5.51% |
| Armistice Capital, LLC | 3.83% |
| Adage Capital Partners GP L.L.C. | 3.07% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.34% |
| Vanguard Group | 8.3% |
| State Street | 8.25% |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
From 4d Molecular Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)
Key Strengths & Strategy (as disclosed to the SEC)
- 4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
- The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
- It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| STOK | Stoke Therapeutics, Inc. | USD 29.3 | ▲ 1.17% |
| NKTX | Nkarta, Inc. | USD 2.27 | ▼ 5.81% |
| ANNX | Annexon, Inc. | USD 5.22 | ▼ 0.19% |
| ALXO | ALX Oncology Holdings Inc. | USD 2.03 | ▲ 0.5% |
| CGEM | Cullinan Therapeutics, Inc. | USD 17.1 | ▼ 3.12% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:04 UTC. This page is informational and not investment advice.